U.S. Markets open in 17 mins.

ACADIA Pharmaceuticals Inc. (ACAD)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
37.63+0.78 (+2.12%)
At close: 4:00PM EDT
People also watch

ACADIA Pharmaceuticals Inc.

3611 Valley Centre Drive
Suite 300
San Diego, CA 92130
United States

Full Time Employees420

Key Executives

Mr. Stephen R. Davis J.D.Chief Exec. Officer, Pres and Director1.13MN/A56
Mr. Todd S. YoungChief Financial Officer and Exec. VP409.1kN/A45
Mr. Glenn F. BaityExec. VP, Gen. Counsel and Sec.N/AN/A47
Dr. Srdjan R. Stankovic M.D., M.S.P.H.Head of R&D and Exec. VP709.79kN/A60
Mr. James A. NashSr. VP of Technology Devel. & OperationsN/AN/A66
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. Its lead product candidate, NUPLAZID, has completed the Phase III pivotal trials for the treatment of Parkinson’s disease psychosis and the Phase II trial for the treatment of schizophrenia, as well as is in Phase II study for the treatment of Alzheimer’s disease psychosis. The company has a collaboration with Allergan, Inc. for the development of product candidates related to chronic pain. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.

Corporate Governance

ACADIA Pharmaceuticals Inc.’s ISS Governance QualityScore as of September 1, 2017 is 8. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 8; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.